🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Harbin
Clinical trial register · China

Clinical Trials in Harbin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Harbin Medical University24 AstraZeneca24 Eli Lilly and Company20 Hoffmann-La Roche16 Bristol-Myers Squibb16
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Harbin

545 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation
NCT07349498Hematopoietic Stem Cell Transplantation, Transplant Complication, Cardiovascular Events
Peking University People's Hospital
Observational
10,000
Beijing, Chongqing, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Xi'an
2026-01-01
Recruiting
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
NCT07266116Systemic Light Chain Amyloidosis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
70
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guiyang, Baoding, Harbin
2025-12-26
Recruiting
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
NCT07235202Pancreatic Ductal Adenocarcinoma (PDAC)
Shenzhen Majory Biotechnology Co., Ltd.
Phase 1/2
45
Beijing, Guangzhou, Harbin, Changchun
2025-12-24
Recruiting
Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma
NCT07248956Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 2
116
Harbin, Jinan, Beijing, Shanghai, Tianjin
2025-12-22
Recruiting
Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients
NCT07294209Acute Ischemic Stroke Patients
Southwest Hospital, China
Phase 4
798
Chongqing, Harbin, Zhoukou, Anshan, Anyang, Baoshan, Bijie, Dali
2025-12-19
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
ArriVent BioPharma, Inc.
Phase 3
480
Beijing, Xiamen, Foshan, Shantou, Shijiazhuang, Harbin, Luoyang, Xinxiang
2025-12-17
Not yet open
Multicenter Study on Early Arterial Changes in Prediabetic Patients Evaluated by Ultra-High-Frequency Ultrasound
NCT07271745Prediabetes
Chunyan Ma
Observational
1,740
Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou, Nanjing, Nanchang, Changchun
2025-12-15
Recruiting
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
NCT07127822Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer
Peking University
Phase 2
106
Shijiazhuang, Harbin, Zhengzhou, Nanjing, Xi'an, Qingdao, Taiyuan, Chengdu
2025-12-15
Recruiting
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
NCT07307235Type 2 Diabetes
Shanghai Zhongshan Hospital
Phase 4
1,316
Hefei, Huizhou, Shenzhen, Harbin, Xinxiang, Wuhan, Changsha, Hengyang
2025-12-13
Active, closed
Efficacy and Safety of ZT006 in Overweight and Obese Participants
NCT07230132Overweight , Obesity
Beijing QL Biopharmaceutical Co.,Ltd
Phase 2
184
Handan, Langfang, Harbin, Luoyang, Chenzhou, Yueyang, Nanjing, Jinan
2025-12-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-12-12
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT07222267Breast Cancer, Advanced Solid Tumor
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Nanjing, Shanghai, Tianjin
2025-12-11
Recruiting
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury
Vantive Health LLC
Not applicable
99
Beijing, Guangzhou, Shenzhen, Harbin, Nanjing, Nanchang, Shanghai, Chengdu
2025-12-11
Recruiting
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
NCT07226349Advanced Solid Tumor
BeOne Medicines
Phase 1
105
Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang
2025-12-11
Recruiting
NWRD06 DNA Plasmid for HCC After Curative Resection.
NCT07324304Hepatocellular Carcinoma (HCC)
Newish Technology (Beijing) Co., Ltd.
Phase 2
30
Beijing, Harbin, Hangzhou
2025-12-08
Active, closed
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
NCT07263776Acute Ischemic Stroke
Capital Medical University
Phase 3
692
Suzhou, Zhangzhou, Qinzhou, Langfang, Qinhuangdao, Tangshan, Harbin, Anyang
2025-12-05
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
Merck Sharp & Dohme LLC
Phase 2
150
Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang
2025-12-04
Recruiting
A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
NCT07042802Ovarian Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
180
Beijing, Fuzhou, Guangzhou, Harbin, Anyang, Zhengzhou, Xuzhou, Shenyang
2025-12-02
Recruiting
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
NCT06514508Multiple Myeloma
Guangzhou Gloria Biosciences Co., Ltd.
Phase 3
60
Beijing, Harbin
2025-12-01
Recruiting
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
NCT07182682Non-Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Not yet open
A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography
NCT07292896Healthy Adults, Pulmonary Hypertension, Tricuspid Regurgitation, Heart Failure
First Hospital of China Medical University
Observational
2,640
Chongqing, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Xiangyang, Changchun
2025-12
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO-resistant sqNSCLC
Takeda
Phase 3
600
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang
2025-11-26
Recruiting
A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia
NCT07229937Hyperlipidemia
Shandong Suncadia Medicine Co., Ltd.
Phase 2
189
Harbin
2025-11-25
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
Summit Therapeutics
Phase 3
600
Beijing, Fuzhou, Guangzhou, Foshan, Shenzhen, Haikou, Shijiazhuang, Harbin
2025-11-18
Recruiting
Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation
NCT07277907Slow Transit Constipation, Pharmacotherapy
Third Military Medical University
Phase 3
346
Bishan, Hechuan, Shapingba, Yuzhong, Lanzhou, Shijiazhuang, Harbin, Wuhan
2025-11-13
Recruiting
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
NCT07361003Refractory Metastatic Colorectal Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
464
Fuzhou, Harbin, Nanjing, Jinan, Tianjin, Hangzhou
2025-11-12
Recruiting
Real-world Study of Aflibercept 8 mg in nAMD
NCT07640997Neovascular Age-Related Macular Degeneration (nAMD)
Peking University People's Hospital
Observational
300
Beijing, Fuzhou, Shenzhen, Zunyi, Harbin, Nanyang, Wuhan, Hohhot
2025-11-11
Recruiting
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
NCT06902740Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
300
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2025-11-07
Recruiting
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
NCT07187440Fabry Disease
Takeda
Observational
200
Hefei, Beijing, Fuzhou, Hangzhou, Shantou, Shenzhen, Shijiazhuang, Harbin
2025-11-01
Not yet open
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
NCT07187960Follicular Lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
228
Beijing, Chongqing, Lanzhou, Guangzhou, Guiyang, Haikou, Harbin, Zhengzhou
2025-11
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
Eli Lilly and Company
Phase 3
1,205
Beijing, Chengdu, Guangzhou, Harbin, Luoyang Shi, Nanjing, Shanghai, Tianjin
2025-10-31
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Hoffmann-La Roche
Phase 3
600
Nanchang, Beijing, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nantong
2025-10-24
Recruiting
Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
NCT07469267Breast Cancer, Radiotherapy
Fudan University
Not applicable
1,608
Guiyang, Shijiazhuang, Harbin, Wuhan, Changde, Changsha, Dalian, Jinan
2025-10-24
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb
Phase 2/3
470
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Luoyang, Zhengzhou
2025-10-23
Recruiting
A Study of AK138D1 in Advanced Malignant Tumors
NCT07281326Solid Cancer
Akeso
Phase 1
200
Harbin
2025-10-22
Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
NCT07111546Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd
Phase 2
140
Hefei, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Xiangyang, Changsha
2025-10-20
Recruiting
KD Treatment for Super-refractory Status Epilepticus
NCT07496749Super-refractory Status Epilepticus
Xuanwu Hospital, Beijing
Not applicable
84
Hefei, Beijing, Fuzhou, Nanning, Guiyang, Haikou, Shijiazhuang, Harbin
2025-10-20
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou
2025-10-15
Recruiting
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
NCT07077434Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Not yet open
Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP
NCT07200336Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Eye & ENT Hospital of Fudan University
Phase 4
360
Chongqing, Fuzhou, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2025-10-08
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S
Phase 3
1,280
Hefei, Beijing, Changchun, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Harbin
2025-10-02
Not yet open
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
NCT07206264Mantle Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
45
Fuzhou, Shijiazhuang, Harbin, Jinan, Tianjin
2025-10
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
NCT07200375Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Pfizer
Phase 3
680
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Wuhan
2025-09-29
Recruiting
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou
2025-09-25
Recruiting
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
NCT07152405Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
490
Harbin, Shanghai
2025-09-24
Recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2
NCT07139314Ischemic Stroke, Atrial Fibrillation
Capital Medical University
Not applicable
240
Ma’anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-24
Recruiting
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
NCT07141706Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1
253
Guangzhou, Harbin, Zhengzhou, Jinan
2025-09-23
Recruiting
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Harbin, Shanghai, Hangzhou
2025-09-22
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
Bristol-Myers Squibb
Phase 3
3,040
Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin
2025-09-22
Recruiting
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
NCT07164170Non-Small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd
Phase 2
86
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2025-09-22
Recruiting
JS207 Combination Therapy in Triple-negative Breast Cancer
NCT07045311Triple-negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin
2025-09-16
Not yet open
Multicenter Validation Study on Autism Screening Using a Machine-assisted System
NCT07006948Autism Spectrum Disorder, Early Developmental Impairment, Language Development Disorders
Children's Hospital of Fudan University
Observational
1,000
Hefei, Xiamen, Liuzhou, Harbin, Kunshan, Xi'an, Shanghai, Chengdu
2025-09-15
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
Eli Lilly and Company
Phase 3
800
Baotou, Beijing, Chongqing, Harbin, Hefei, Jinan, Luoyang, Nanjing
2025-09-15
Not yet open
A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
NCT07146126Seasonal Allergic Rhinitis, SAR
Prime Gene Therapeutics Co., Ltd.
Phase 3
600
Beijing, Lanzhou, Baoding, Cangzhou, Langfang, Shijiazhuang, Daqing, Harbin
2025-09-15
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
Bristol-Myers Squibb
Phase 2/3
600
Hefei, Beijing, Fuzhou, Fyzhou, Xiamen, Lanzhou, Nanning, Harbin
2025-09-11
Recruiting
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
NCT07102901Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
351
Harbin, Zhengzhou
2025-09-05
Recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation
NCT07139301Ischemic Stroke, Atrial Fibrillation
Capital Medical University
Not applicable
438
Ma’anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-04
Recruiting
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT07169994Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
414
Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang
2025-09-02
Recruiting
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
NCT07304232Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
134
Shijiazhuang, Harbin, Tianjin
2025-09-01
Not yet open
A Study on Cardiopulmonary Exercise Tolerance Standards for Healthy Chinese Population
NCT07108296Oxygen Consumption, Cardiorespiratory Fitness
Affiliated Hospital of Changchun University of Chinese Medicine
Observational
4,620
Beijing, Quanzhou, Guangzhou, Nanning, Daqing, Harbin, Puyang, Zhengzhou
2025-09-01
Not yet open
Efficacy and Safety of a New Balloon Microcatheter in the Treatment of Intracranial Artery Stenosis
NCT07170618Intracranial Artery Stenosis
Sinomed Neurovita Technology Inc.
Not applicable
56
Harbin
2025-09-01
Recruiting
Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens
NCT07694648Respiratory Tract Infections (RTI), Respiratory Syndrome, Acute, Severe, Acute Respiratory Infections (ARIs)
Huashan Hospital
Observational
2,398
Beijing, Guangzhou, Zhuhai, Shijiazhuang, Harbin, Jiamusi, Shangqiu, Zhengzhou
2025-09-01
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Beijing, Harbin, Zhengzhou
2025-08-28
Recruiting
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT07133750CRC (Colorectal Cancer)
Biotheus Inc.
Phase 2
100
Beijing, Guangzhou, Harbin, Wuhan, Changchun, Jinan, Shanghai, Chengdu
2025-08-19
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Amgen
Phase 3
350
Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai
2025-08-18
Recruiting
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
NCT07023315Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Akeso
Phase 3
760
Beijing, Fuzhou, Shijiazhuang, Harbin, Shanghai, Tianjin
2025-08-14
By invitation
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT07376629TNBC
Huabo Biopharm Co., Ltd.
Phase 2
60
Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin
2025-08-14
Recruiting
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
NCT07105215Solid Tumors
RemeGen Co., Ltd.
Phase 1/2
312
Beijing, Fuzhou, Xiamen, Guilin, Nanning, Harbin, Luoyan, Luoyang
2025-08-11
Active, closed
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
NCT07162181Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
Eli Lilly and Company
Phase 2
13
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan
2025-08-07
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
Sanofi
Phase 3
723
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot
2025-08-06
Recruiting
Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation
NCT06871228Atrial Fibrillation (AF)
Beijing Anzhen Hospital
Not applicable
4,100
Hefei, Beijing, Guangzhou, Shijiazhuang, Harbin, Luohe, Zhengzhou, Wuhan
2025-08-05
Recruiting
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
NCT07124936Diffuse Large B Cell Lymphoma (DLBCL)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
97
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Changsha
2025-07-30
Recruiting
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
NCT07079475Non-Small Cell Lung Cancer
Dizal Pharmaceuticals
Phase 1/2
220
Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Shengyang, Jinan
2025-07-30
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502Follicular Lymphoma
Celgene
Phase 3
400
Beijing, Fuzhou Fujian, Guangzhou, Harbin, Wuhan, Changsha, Hohhot, Suzhou
2025-07-28
Recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Amgen
Phase 3
12,800
Bengbu, Beijing, Guangzhou, Huizhou, Yulin, Qinhuangdao, Shijiazhuang, Harbin
2025-07-25
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
714
Hefei, Beijing, Fuzhou, Guangzhou, Huizhou, Nanning, Harbin, Luoyang
2025-07-23
Recruiting
Chinese Migrant Population Health Cohort
NCT07124949Cardiovascular Diseases, Metabolic Disorders, Ageing and Geriatric Health, Climate Adaptation
Jinwei Tian
Observational
26,000
Harbin
2025-07-23
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
PharmaEssentia
Phase 3
160
Beijing, Chongqing, Guangdong, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2025-07-18
Active, closed
A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors
NCT07387874Recurrent or Metastatic Solid Tumors
Lixiaoling
Observational
30
Harbin
2025-07-10
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
Safety and Efficacy of Ventricular Irrigation for Ventriculitis
NCT06358209Central Nervous System Infections
RenJi Hospital
Not applicable
310
Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Shenzhen, Zhongshan, Harbin
2025-07-01
Recruiting
Rectal NSAIDs With/Without PD Stent for PEP Prevention
NCT07117318Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs, Pancreatic Duct Stent Placement
Air Force Military Medical University, China
Not applicable
1,278
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Xi'an
2025-07-01
Not yet open
Cardiovascular Risk Early Screening and Warning in Harbin : A Prospective Cohort Study
NCT07033624Cardiovascular Diseases
Harbin Medical University
Observational
10,000
Harbin
2025-07-01
Recruiting
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
NCT07071090Solid Tumor Malignancies
Heronova Pharmaceuticals
Phase 1
32
Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha, Jinan, Hangzhou
2025-06-30
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Amgen
Phase 3
5,056
Hefei, Beijing, Guangzhou, Haikou, Qinhuangdao, Shijiazhuang, Harbin, Kaifeng
2025-06-25
Recruiting
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
642
Hefei, Beijing, Lanzhou, Shantou, Harbin, Kaifeng, Puyang, Zhengzhou
2025-06-23
Recruiting
Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy
NCT07030881Asthma, COPD
First Affiliated Hospital of Ningbo University
Not applicable
380
Hefei, Harbin, Ningbo, Ninghai, Taizhou
2025-06-17
Recruiting
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
NCT06953999Pancreatic Cancer
Akeso
Phase 3
999
Harbin, Shanghai, Hangzhou
2025-06-11
Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
NCT06783647Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd
Phase 2
250
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Guilin, Nanning, Harbin
2025-06-11
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
630
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-06-11
Recruiting
Indomethacin vs Diclofenac for Preventing PEP
NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin
Air Force Military Medical University, China
Not applicable
4,050
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City
2025-06-01
Not yet open
Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
NCT07010588Hepatocellular Carcinoma (HCC), Magnetic Resonance Imaging (MRI), Randomized Controlled Trial
Peking University People's Hospital
Not applicable
1,389
Beijing, Chongqing, Handan, Harbin, Wuhan, Changchun, Jinan, Qingdao
2025-06
Recruiting
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
NCT06954467Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Not yet open
Study on the Mechanism of Multi-group Analysis of the Influence of Depression on Common Cardiovascular Diseases
NCT06975592Depression and CVD
First Affiliated Hospital of Harbin Medical University
Observational
300
Harbin
2025-05-25
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
500
Hefei, Fuzhou, Guangzhou, Harbin, Zhenngzhou, Wuhan, Xining, Shanghai
2025-05-22
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
Eli Lilly and Company
Phase 3
600
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-19
Rows per page Showing 101–200 of 545
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/harbin?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 545 of those studies with a site in Harbin.

How many clinical trials are recruiting in Harbin?

308 of the 545 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 60 have not yet opened recruitment, 171 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.